According to our new research study on “Metastatic Cancer Drug Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Cancer Type, Route of Administration, Drug Class, Product, and End User,” the metastatic cancer drug market size is expected to grow from US$ 51,157.97 million in 2021 to US$ 68,349.54 million by 2028. It is estimated to grow at a CAGR of 4.2% from 2021 to 2028. Factors driving the market’s growth are the high prevalence of metastatic cancer and government initiatives to support developments in cancer treatment.

Get Your Free Sample Copy Today | Click Here: https://www.theinsightpartners.com/sample/TIPRE00028616

Government organizations of various countries are introducing missions and programs for quick and effective cancer treatment. In 2016, the Government of the US launched the        Cancer Moonshot with three ambitious goals: To accelerate scientific cancer-related discovery, foster greater collaboration, and improve data sharing. The cancer patient community and medical researchers responded with tremendous energy and ingenuity to this campaign. On February 2, 2022, the Cancer Moonshot project was relaunched by highlighting new goals of reducing the death rate of cancer by at least 50% over the next 25 years, improving the experience of people and their families living with and surviving cancer, and putting an end to cancer through these efforts. By focusing on the areas of cancer research and encouraging new investments that are most likely to benefit patients, the Cancer Moonshot has brought together a large community of investigators and clinicians dedicated to expediting research to improve patient lives.

In 2020, 2.7 million people in the European Union were diagnosed with the disease, and another 1.3 million people lost their lives to it. The EU has been working to tackle cancer for decades, and its actions, for example, tobacco control and protection from hazardous substances, have saved and prolonged lives. Europe’s Beating Cancer Plan is the EU’s response to the need for cancer treatment. It reflects a political commitment to leave no stone unturned to take action against cancer. Mobilizing the collective power of the EU to drive change for the benefit of the citizens, the Cancer Plan contains concrete, ambitious actions that will support, coordinate and complement Member States’ efforts to reduce the suffering caused by cancer. Over the coming years, it will focus on research and innovation, tap into the process of digitalization and offer new technologies, and mobilize financial instruments to support the Member States.

F. Hoffmann-La Roche Ltd; AbbVie Inc.; Amgen Inc.; Novartis AG; ASTRAZENECA PLC.; Eli Lily and Company; Merck KGaA; Pfizer Inc.; Johnson & Johnson Services, Inc.; and Bristol-Myers Squibb Company are the leading companies operating in the metastatic cancer drug market.

The metastatic cancer drug market is analyzed on the basis of cancer type, route of administration, drug class, product, end user, and geography.

The metastatic cancer drug market is analyzed on the basis of cancer type, route of administration, drug class, product, end user, and geography. Based on cancer type, the market is segmented into breast cancer, lung cancer, liver cancer, hematological cancer, brain cancer, prostate cancer, pancreatic cancer, and others. Based on route of administration, the market is segmented into intravenous, intramuscular, oral, and others. Based on drug class, the metastatic cancer drug market is segmented into HER2 inhibitors, immune checkpoint inhibitors, PARP inhibitors, kinase inhibitors, and others. Based on product, the market is bifurcated into branded products and generics and biosimilars. Based on end user, the market is segmented into hospitals, specialty clinics, and others.

By geography, the metastatic cancer drug market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

About US

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Metastatic Cancer Drug, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Food and Beverages, Consumers and Goods, Chemicals and Materials.

Contact US

Contact Person : Ankit Mathur

Phone : +1-646-491-9876

E-mail : [email protected]